Operating Income - Theriva Biologics Inc (F:SFY) - Alpha Spread

Theriva Biologics Inc
F:SFY

Watchlist Manager
Theriva Biologics Inc Logo
Theriva Biologics Inc
F:SFY
Watchlist
Price: 2.42 EUR
Market Cap: 41.8m EUR
Have any thoughts about
Theriva Biologics Inc?
Write Note

Theriva Biologics Inc
Operating Income

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Theriva Biologics Inc
Operating Income Peer Comparison

Comparables:
ABBV
GILD
AMGN
VRTX
REGN

Competitive Operating Income Analysis
Latest Figures & CAGR of Competitors

Company Operating Income CAGR 3Y CAGR 5Y CAGR 10Y
Theriva Biologics Inc
F:SFY
Operating Income
-$21.6m
CAGR 3-Years
-31%
CAGR 5-Years
-6%
CAGR 10-Years
-4%
Abbvie Inc
NYSE:ABBV
Operating Income
$16B
CAGR 3-Years
-1%
CAGR 5-Years
5%
CAGR 10-Years
10%
Gilead Sciences Inc
NASDAQ:GILD
Operating Income
$10.3B
CAGR 3-Years
2%
CAGR 5-Years
4%
CAGR 10-Years
0%
Amgen Inc
NASDAQ:AMGN
Operating Income
$6.2B
CAGR 3-Years
-11%
CAGR 5-Years
-9%
CAGR 10-Years
-1%
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
Operating Income
$4.2B
CAGR 3-Years
23%
CAGR 5-Years
36%
CAGR 10-Years
N/A
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
Operating Income
$4.2B
CAGR 3-Years
-14%
CAGR 5-Years
14%
CAGR 10-Years
17%

See Also

What is Theriva Biologics Inc's Operating Income?
Operating Income
-21.6m USD

Based on the financial report for Mar 31, 2024, Theriva Biologics Inc's Operating Income amounts to -21.6m USD.

What is Theriva Biologics Inc's Operating Income growth rate?
Operating Income CAGR 10Y
-4%

Over the last year, the Operating Income growth was 4%. The average annual Operating Income growth rates for Theriva Biologics Inc have been -31% over the past three years , -6% over the past five years , and -4% over the past ten years .

Back to Top